Anticoagulant

The usage of anticoagulant therapy is one of the most common forms of medical intervention. The CHADS2 score is the simplest and most commonly used stroke- risk assessment tool since its implementation 2001. This scale is used to determine whether or not anticoagulation therapy is required for patients with episodic atrial fib. A higher CHADS2 score is directly related to a greater risk of stroke. The level of risk from a thrombotic event is determined by a score which is tallied by including

A New Generational Anticoagulant For many year’s patients with atrial fibrillation have been treated with anticoagulants such as Warfarin to prevent strokes and embolisms. Unfortunately, Warfarin must be closely monitored and that is an irritant for some patients. In October 2010, the FDA approved a new generational anticoagulant drug called Dabigatran (Pradaxa). This alternate medication gives patients the benefit of no dietary restrictions since dabigatran is not affected by certain foods. Another

Preventing errors relating to commonly used anticoagulants. (2008). Joint Commission perspectives. Joint Commission on Accreditation of Healthcare Organizations, 28(11), 13-15. From 1997 to 2007 anticoagulants have been identified as one of the top five drug types associated with patient safety in the United States. There is a big concern with patient education and medication administration in the hospital. In the hospital common problems included lack of standardization for the naming, labeling

In a hospital setting, anticoagulants and antiplatelets are widely prescribed by physicians because of their greater benefits in changing the physiological homeostasis of the cardiovascular system. Anticoagulants and antiplatelets play a fundamental role in the treatment of cardiovascular diseases as they are very effective at counteracting the different symptoms cardiovascular

negative example related to the use of mammalian heparin, which took place in Brazil, was the increase of bleeding when porcine intestinal heparin was replaced by bovine intestinal heparin [7,11]. Heparin has been the most clinically exploited anticoagulant over the last 50 years (Fareed et al., 2000). To overcome these issues, different low molecular-weight heparins have been produced using a variety of methods, including chemical depolymerization and enzymatic digestion (Hirsh and Raschke,

1.The Organization that developed Prevention of VTE in Orthopedic Surgery Patients: Antithrombic Therapy and Prevention of Thrombosis is The American College of Chest Physicians-Medical Specialty Society. 2.No stakeholders known of in the speciality. 3.) The founders of The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines are: •National Heart, Lung, and Blood Institute [R13 HL104758] •Bayer Schering

Co., must develop a positioning strategy that maximizes the perceived value of Angiomax. Medicines Co. must first determine the critical characteristics its key customer segments (doctors, hospital administrators, and pharmacists) value in an anticoagulant

Introduction Our body system is not immune to pathological deficiencies. There exist numerous identified pathologies which compromise the regular functioning of a heart, but all heart-related pathologies are narrowed to a single condition known as Acute Coronary Syndrome (ACS). This is the term properly used in reference to the different identified clinical entities threatening the cardiovascular system. ACS is the result of the progressive or complete sudden blocking of the arteries or veins;

Page 8 Page 9 ISSN 2320-5407 International Journal of Advanced Research (2015), Volume 3, Issue 12, 1539 –15481546INR levels were less in PVT group than control group but in patients with early stages of liver cirrhosis, no differences in their levels was found between the 2 groups. Therefore, patients with advanced liver cirrhosis and less prolonged coagulation parameters appear to carry a higher risk of PVT compared with patients with advanced liver cirrhosis

arteries with lethal consequences. There are several drugs that resolve/prevent DVT, but only two major drugs will be addressed. Nurses will most likely see Warfarin and Heparin prescribed to a patient to treat DVT. The first drug, Warfarin, is an anticoagulant. It is a Vitamin K inhibitor which means that it blocks the activation of Vitamin K, decreasing the production of Vitamin K clotting factors, which are factors VII, IX, X and prothrombin (PME). Warfarin has a few side effects to keep in considerations